By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Most loved Road Food: Which One Prevails upon You? - 2Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- 3Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- 4A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- 5Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Boats escort freed whale away from shallow waters off German coast
- Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- Four new luxury hotel openings in Italy you need to know about
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- 2024's Savvy Home Gadgets for an Associated Way of life
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- From Modesty to Administration: Self-improvement in Interactive abilities
- 6 US States for Fly Fishing
- China resumes flights to North Korea after a six-year pause
